The China Scar Treatment Market is anticipated to grow at a CAGR of 11.5% with USD 444.4 Mn in 2026 and is expected to reach USD 1,070.7 Mn in 2033. Consumers in China are increasing demand for scar treatment solutions as they seek aesthetic procedures, advanced skincare products, and improved appearance outcomes. Approximately 20 Mn people in China undergo cosmetic procedures annually, with women accounting for about 80% of patients and the average patient age around 25 years. About 82% of consumers prefer non-surgical treatments, such as injectables, over invasive surgical procedures.
|
Current Event |
Description and its Impact |
|
NHSA Standardized Medical Service Price Reform (2025) |
|
|
Continued Expansion of DRG/DIP Payment Reform |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Topical Scar Products hold the largest market share of 41.6% in 2026. Consumers are driving the growth of topical scar products in China’s scar treatment market by increasing their focus on skin health and seeking non-invasive scar management solutions. Rising concerns about acne scars, surgical scars, and injury-related marks are encouraging greater product adoption. Younger consumers are showing stronger interest in beauty and skincare, while e-commerce expansion, product innovation, and higher disposable income are improving market access. Silicone gels, scar creams, and advanced skincare formulations are enabling consumers to manage scars conveniently through home-based treatments. For instance, Galderma announced the U.S. availability of EPSOLAY (benzoyl peroxide) Cream, 5% after FDA approval. EPSOLAY is the first microencapsulated benzoyl peroxide treatment proven to provide rapid and sustained relief from rosacea bumps and blemishes.
Laser expected to hold largest market share of 38.9% in 2026 owing to the rising demand for cosmetic appearance enhancement. Consumers and healthcare providers are accelerating the growth of laser treatment in China’s scar treatment market by increasing demand for advanced aesthetic procedures and minimally invasive solutions. Growing awareness of skin appearance encourages patients to seek effective treatments for acne scars, surgical scars, and trauma-related scars. Dermatology clinics are expanding their laser treatment offerings, while technological advancements in laser devices and the growth of medical aesthetics services are improving adoption. Rising spending on cosmetic treatments further strengthens the use of laser-based scar management procedures. China's medical aesthetics market was valued at CNY 200 billion in 2021 and is projected to reach CNY 400 billion by 2025.

To learn more about this report, Request Free Sample
Clinics acquired the largest market share of 42.2% in 2026. Consumers and healthcare providers are driving the growth of clinics in China’s scar treatment market by increasing demand for professional scar management services and advanced dermatological procedures. China has more than 13,000 licensed medical aesthetic clinics operating across the country. Rising aesthetic awareness encourages patients to seek personalized treatments for acne scars, surgical scars, and injury-related scars, resulting in more clinic visits. Medical aesthetics centers are expanding their services, while advanced technologies, skilled specialists, and expert-led care improve treatment adoption. Clinics are also using digital marketing and enhanced healthcare access to attract and serve more patients.
Some of the major key players in China Scar Treatment are Cynosure, Inc., Syneron Medical Ltd., Mölnlycke Health Care, Ostar Beauty Sci-Tech Co., Ltd., Shanghai Fosun Pharmaceutical Co. Ltd., Beijing Toplaser Technology Co., Ltd., Merz Pharma, and Luca Pharmaceuticals.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 444.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.5% | 2033 Value Projection: | USD 1,070.7 Mn |
| Segments covered: |
|
||
| Companies covered: |
Cynosure, Inc., Syneron Medical Ltd., Mölnlycke Health Care, Ostar Beauty Sci-Tech Co., Ltd., Shanghai Fosun Pharmaceutical Co. Ltd., Beijing Toplaser Technology Co., Ltd., Merz Pharma, and Luca Pharmaceuticals. |
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients